FundedIQ
Biotechnology

Slate Medicines: Funding, Investors & Team (Sep 2026)

Slate Medicines is a biotechnology company that develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention. The company aims to revolutionize migraine prevention for patients seeking alternative solutions.

www.slatemedicines.com LinkedIn Raleigh, United States 1-10 employees
Biotechnology Medical Therapeutics
Total raised
$130M
Rounds
1
Latest
Series A
Feb 2026

Slate Medicines has raised $130M across 1 funding round on record, the most recent a Series A of $130M announced in Feb 2026.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Slate Medicines Company Profile and Key Stats

Total funding raised
$130M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series A
$130M in Feb 2026
Employees
1-10
reported band
Headquarters
Raleigh, United States

Latest funding round on record: Feb 2026.

Slate Medicines Funding Rounds

Date
Round
Amount
Series A
$130M

Slate Medicines Founders and Leadership Team

Name
Role
Contact
Neil Buckley
Founder

No contact details are on record for this team yet.

Slate Medicines Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
29,722
$7.5M
8,352
$15M

Slate Medicines' latest round of $130M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Slate Medicines in Biotechnology and Raleigh

Companies Similar to Slate Medicines

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…

Series A $6.3M

Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.

Series C $90.0M

Cataract surgery is the single most common procedure performed in the United States annually. Despite…

Series A $7.0M

InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…

Convertible Note $1.3M

Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…

Series A $10.0M

Slate Medicines Funding FAQs

What does Slate Medicines do?

Slate Medicines is a biotechnology company that develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention. The company aims to revolutionize migraine prevention for patients seeking alternative solutions.

How much funding has Slate Medicines raised?

Slate Medicines has raised $130M across 1 round on record. The most recent is a Series A of $130M announced in Feb 2026.

When did Slate Medicines last raise funding?

Slate Medicines' most recent funding round on record is a Series A of $130M, announced in Feb 2026.

Who founded Slate Medicines?

FundedIQ lists Neil Buckley (Founder) at Slate Medicines.

Where is Slate Medicines headquartered?

Slate Medicines is based in Raleigh, North Carolina, United States.

How many employees does Slate Medicines have?

Slate Medicines is in the 1-10 employee band.

How does Slate Medicines' funding compare to other Biotechnology startups?

Slate Medicines' latest round of $130M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Slate Medicines Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Slate Medicines is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.